Mock Recall: What It Is, What FDA Says, and a Readiness Checklist

Short answer: a mock recall is a practice exercise in which a firm tests its own recall procedures as if a product had to be pulled from the market. FDA’s voluntary-recall guidance says a firm that anticipates complex recalls “may want to consider” mock recalls to verify its recall readiness. It is recommended practice. FDA’s 21 CFR 7.59 is general industry guidance for recall preparation and does not mention mock recalls. This page is general regulatory information, not legal or individual advice.

Definition and scope

A recall, in FDA’s words, is an action taken by a firm to remove a product from the market (FDA, “Recalls Background and Definitions”). A mock recall rehearses that action without an actual safety problem driving it. FDA’s guidance, Initiation of Voluntary Recalls Under 21 CFR Part 7, Subpart C (March 2022, nonbinding), says mock recalls “familiarize personnel with the recall process and may improve the effectiveness of the firm’s recall program.”

The guidance does not give a formal definition of the term, set a frequency, or set a pass mark. Anything more specific than that, such as a required completion time, comes from a firm’s own plan or an auditor’s expectations, not from FDA’s guidance.

How it is used in practice

FDA lists “general preparations” a firm can make before any recall, and the mock recall appears in the same bullet as personnel training. A drill is most useful when it exercises each of those preparations. The checklist below is built only from that FDA list.

Preparation FDA describes	What a drill can check
Identify personnel with recall responsibilities and authority; consider alternates; a “recall team” with a recall coordinator and decision-makers may suit complex recalls	Whether the named people, and their alternates, could be reached and could act
Train personnel “on a regular basis”	Whether staff understood the procedures they were asked to perform
Establish a recall communications plan covering internal communications, FDA, and direct accounts or the public, with points of contact identified ahead of time and draft templates such as notification letters to direct accounts	Whether the contacts and templates existed and could be used promptly
Use “sufficient coding” of regulated products to allow positive lot identification (21 CFR 7.59(b))	Whether an affected lot could be identified from the product’s coding
Maintain distribution records to help locate products being recalled (21 CFR 7.59(c))	Whether the records showed where affected product went
Prepare, maintain and document written procedures for initiating a recall that assign responsibility and describe the steps	Whether the written procedure matched what people actually did
Consider establishing metrics appropriate to the recall plan	Which measures the firm chose to record, and how the drill performed against them

FDA also says that if a firm is not satisfied with the results of a mock or actual recall, it should consider modifying procedures or training its personnel. Plans and initiation procedures should be specific to the firm or facility, so a drill scenario should follow the firm’s own distribution chain rather than a generic template.

Related concepts: recall classes

Scenario severity can be framed using FDA’s recall classifications, which describe the health hazard of the product, not the drill itself.

Class	FDA description
Class I	A reasonable probability that use of or exposure to the product will cause serious adverse health consequences or death
Class II	Use or exposure may cause temporary or medically reversible adverse health consequences, or the probability of serious adverse health consequences is remote
Class III	Use or exposure is not likely to cause adverse health consequences

FDA also distinguishes a market withdrawal, which involves a minor violation that would not be subject to FDA legal action. Source: FDA, Recalls Background and Definitions.

Where it matters for labs, clinics and supply decisions

The phrase turns up in audit questions. A GMP audit checklist can ask whether a facility has a documented complaint-handling and product-recall procedure, including mock recall exercises, and a food safety audit checklist can ask for a tested mock recall procedure with documented time to completion. Knowing that FDA treats the drill as recommended practice helps a quality lead explain what is and is not being asked.

The same preparations tie into related records work: medical supply inventory records and recall readiness (lot and expiry tracking), ISO 13485 certification for medical device quality systems, deviation management, and root cause analysis for reviewing what a drill or real event exposed. For what a real recall looks like, see the page on a contact lens solution recall.

Common misunderstandings

• “The regulation requires a mock recall.” 21 CFR 7.59 is itself headed “General industry guidance” and is offered as guidance for a firm’s consideration, not as a mandate. Section 7.59(a) recommends a current written contingency plan for initiating and effecting a recall. It does not mention mock recalls. The FDA guidance language is “may want to consider.”
• “FDA sets a time limit or success rate.” The guidance sets none. It says to consider metrics appropriate to the firm’s own plan.
• “One generic plan fits every site.” FDA says plans and procedures should be specific to the firm or facility.

FAQ

What is a mock recall?

A rehearsal of a firm’s recall procedures, used to verify recall readiness and familiarize personnel with the process, as described in FDA’s 2022 voluntary-recall guidance.

Does FDA require mock recalls?

No. 21 CFR 7.59 is FDA’s general industry guidance for recall preparation, and its paragraph (a) recommends a written recall contingency plan; it does not mention mock recalls. The guidance, which is nonbinding, suggests firms anticipating complex recalls may want to consider them. An audit standard or customer may ask for them separately.

What should a firm do if a mock recall goes badly?

FDA says to consider modifying procedures or training personnel if the firm is not satisfied with the results of a mock or actual recall.

Sources

• FDA, Initiation of Voluntary Recalls Under 21 CFR Part 7, Subpart C: Guidance for Industry (March 2022; checked 2026-11-03).
• FDA, Recalls Background and Definitions (checked 2026-11-03).
• eCFR, 21 CFR 7.59, General industry guidance (checked 2026-11-03).